"Companion diagnostics": has their time come and gone?

Fred R Hirsch; Paul A Bunn Jr; Roy S Herbst

doi:10.1158/1078-0432.CCR-14-0932

"Companion diagnostics": has their time come and gone?

Clin Cancer Res. 2014 Sep 1;20(17):4422-4. doi: 10.1158/1078-0432.CCR-14-0932. Epub 2014 Jul 24.

Authors

Fred R Hirsch¹, Paul A Bunn Jr², Roy S Herbst³

Affiliations

¹ Department of Medicine and Pathology, University of Colorado Cancer Center, Aurora, Colorado. fred.hirsch@ucdenver.edu.
² Department of Medicine and Pathology, University of Colorado Cancer Center, Aurora, Colorado.
³ Department of Medicine, Smillow Cancer Center, Yale School of Medicine, New Haven, Connecticut.

Abstract

Rapid development of molecularly targeted drugs requires a "companion diagnostic" that could delay drug development and limit availability of active drugs for relevant patients. Were the negative results from MetMab studies in patients with advanced non-small cell lung cancer due to drug failure or failure of the right companion diagnostic?

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Erlotinib Hydrochloride
Female
Humans
Male
Proto-Oncogene Proteins c-met / biosynthesis*
Quinazolines / administration & dosage*

Substances

Antibodies, Monoclonal
Quinazolines
Erlotinib Hydrochloride
MET protein, human
Proto-Oncogene Proteins c-met
onartuzumab

Abstract

Publication types

MeSH terms

Substances

Grants and funding